AVTE – aerovate therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.
Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Form ARS Aerovate Therapeutics, For: Dec 31
Form DEFA14A Aerovate Therapeutics,
Form DEF 14A Aerovate Therapeutics, For: Jun 05
Form 4 Aerovate Therapeutics, For: Apr 17 Filed by: Gillies Hunter
Form 4 Aerovate Therapeutics, For: Apr 17 Filed by: Dake Benjamin T
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.